AstraZeneca Plc's and Sanofi's drug to prevent respiratory syncytial virus won support from a U.S. regulatory panel for use in infants, potentially adding to a group of breakthrough products set to reach pharmacy shelves this year.The 21 advisers to the Food and Drug Administration voted unanimously on Thursday to endorse the medicine for newborns and infants, calling the treatment's safety profile compelling.
[
add
]
[
|
|
...
]